Baseline characteristics in the overall patient population and the discordant and concordant disease progression subgroups
| Discordant subgroup (n=147) | Concordant disease progression subgroup (n=798) | Overall (N=1765) | |
| Median age (range), years | 62.0 (23.0–89.0) | 62.0 (21.0–91.0) | 64.0 (19.0–91.0) |
| Sex, n (%) | |||
| Female | 70 (47.6) | 403 (50.5) | 852 (48.3) |
| Male | 77 (52.4) | 395 (49.5) | 913 (51.7) |
| Race, n (%) | |||
| White | 111 (75.5) | 612 (76.7) | 1331 (75.4) |
| Other | 36 (24.5) | 184 (23.1) | 430 (24.4) |
| Missing | 0 | 2 (0.3) | 4 (0.2) |
| Geographic region, n (%) | |||
| America | 98 (66.7) | 564 (70.7) | 1249 (70.8) |
| Asia | 8 (5.4) | 62 (7.8) | 118 (6.7) |
| Europe | 38 (25.9) | 165 (20.7) | 379 (21.5) |
| Missing | 3 (2.0) | 7 (0.9) | 19 (1.1) |
| ECOG PS, n (%) | |||
| 0 | 61 (41.5) | 256 (32.1) | 671 (38.0) |
| 1 | 86 (58.5) | 542 (67.9) | 1094 (62.0) |
| Tumor size at baseline, n (%) | |||
| <Median | 68 (46.3) | 353 (44.2) | 871 (49.3) |
| ≥Median | 79 (53.7) | 441 (55.3) | 886 (50.2) |
| Not available | 0 | 4 (0.5) | 8 (0.5) |
| Previous lines of therapy, n (%) | |||
| 0 | 59 (40.1) | 250 (31.3) | 691 (39.2) |
| 1 | 30 (20.4) | 232 (29.1) | 435 (24.6) |
| >1 | 58 (39.5) | 316 (39.6) | 639 (36.2) |
| PD-L1 status, n (%) | |||
| Negative | 81 (55.1) | 461 (57.8) | 914 (51.8) |
| Positive | 45 (30.6) | 209 (26.2) | 533 (30.2) |
| Not evaluable | 21 (14.3) | 128 (16.0) | 318 (18.0) |
ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed death ligand 1.